UroGen Pharma (URGN) Revenue & Revenue Breakdown
UroGen Pharma Revenue Highlights
Latest Revenue (Y)
$90.40M
Latest Revenue (Q)
$20.25M
Main Segment (Y)
Jelmyto
UroGen Pharma Revenue by Period
UroGen Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $90.40M | 9.29% |
| 2023-12-31 | $82.71M | 28.52% |
| 2022-12-31 | $64.36M | 33.96% |
| 2021-12-31 | $48.04M | 307.17% |
| 2020-12-31 | $11.80M | 65450.00% |
| 2019-12-31 | $18.00K | -98.40% |
| 2018-12-31 | $1.13M | -86.17% |
| 2017-12-31 | $8.16M | -53.46% |
| 2016-12-31 | $17.53M | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
UroGen Pharma generated $90.40M in revenue during NA 2024, up 9.29% compared to the previous quarter, and up 502211.11% compared to the same period a year ago.
UroGen Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $20.25M | -17.55% |
| 2024-12-31 | $24.57M | -2.54% |
| 2024-09-30 | $25.20M | 15.36% |
| 2024-06-30 | $21.85M | 16.33% |
| 2024-03-31 | $18.78M | -20.18% |
| 2023-12-31 | $23.53M | 12.84% |
| 2023-09-30 | $20.85M | -1.36% |
| 2023-06-30 | $21.14M | 22.96% |
| 2023-03-31 | $17.19M | -4.97% |
| 2022-12-31 | $18.09M | 12.39% |
| 2022-09-30 | $16.10M | -3.05% |
| 2022-06-30 | $16.60M | 22.41% |
| 2022-03-31 | $13.56M | -16.14% |
| 2021-12-31 | $16.17M | 42.49% |
| 2021-09-30 | $11.35M | -12.90% |
| 2021-06-30 | $13.03M | 74.11% |
| 2021-03-31 | $7.49M | -6.04% |
| 2020-12-31 | $7.97M | 130.16% |
| 2020-09-30 | $3.46M | 830.38% |
| 2020-06-30 | $372.00K | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | -100.00% |
| 2019-06-30 | $18.00K | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2018-09-30 | $283.00K | -22.25% |
| 2018-06-30 | $364.00K | -24.32% |
| 2018-03-31 | $481.00K | 47.09% |
| 2017-12-31 | $327.00K | -95.81% |
| 2017-09-30 | $7.81M | 100.00% |
| 2017-06-30 | - | -100.00% |
| 2017-03-31 | $19.00K | -99.89% |
| 2016-12-31 | $17.53M | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | - |
UroGen Pharma generated $20.25M in revenue during Q1 2025, up -17.55% compared to the previous quarter, and up 86.08% compared to the same period a year ago.
UroGen Pharma Revenue Breakdown
UroGen Pharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 18 |
|---|---|---|---|---|---|
| Jelmyto | $90.40M | $82.71M | $64.36M | $48.04M | - |
| R T Gel | - | - | - | - | $1.10M |
Latest
UroGen Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 24: Jelmyto (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jelmyto | $20.25M | $46.41M | $25.20M | $18.78M | $44.38M | $21.14M | $17.19M | $18.09M | $16.10M | $16.60M | $13.56M | $16.17M | $11.35M |
Latest
UroGen Pharma's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Jelmyto (100.00%).
UroGen Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TRDA | Entrada Therapeutics | $210.78M | $37.40M |
| RYTM | Rhythm Pharmaceuticals | $130.13M | $41.83M |
| WVE | Wave Life Sciences | $108.30M | $83.75M |
| ANAB | AnaptysBio | $91.28M | $43.11M |
| URGN | UroGen Pharma | $90.40M | $20.25M |
| YMAB | Y-mAbs Therapeutics | $87.69M | $20.90M |
| FENC | Fennec Pharmaceuticals | $47.54M | $7.92M |
| XOMA | XOMA Royalty | $28.49M | $15.91M |
| KZR | Kezar Life Sciences | - | - |
| SRRK | Scholar Rock | - | - |